๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Relapsed or Refractory Peripheral T-cell Lymphoma

Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas NCT06176690Phase 12 sites๐Ÿ“ Houston๐Ÿ“ Houston Baylor College of Medicine ยท Tests: C7R.CD30.CAR-EBVST cells Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL NCT06874946Phase 1, Phase 21 site๐Ÿ“ Beijing Peking University People's Hospital ยท Tests: CD5-targeted CAR-T cells GVMยฑR in Patients With Relapsed or Refractory Aggressive NHL. NCT06244368Phase 21 site๐Ÿ“ Tianjin Institute of Hematology & Blood Diseases Hospital, China ยท Tests: GVMยฑR regimen A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL NCT06966154Phase 1, Phase 21 site๐Ÿ“ Shanghai Fudan University ยท Tests: tislezumab, golidocitinib, Selinexor A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL NCT06855823Phase 1, Phase 21 site๐Ÿ“ Guangzhou Sun Yat-sen University ยท Tests: Golicitinib combined with Pomadomide Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) NCT06810778Phase 1, Phase 21 site๐Ÿ“ Los Angeles Jonsson Comprehensive Cancer Center ยท Tests: Duvelisib, Venetoclax Evaluate the Safety and Clinical Activity of HH2853 NCT04390737Phase 1, Phase 225 sites๐Ÿ“ Phoenix๐Ÿ“ Jacksonville๐Ÿ“ Rochester Haihe Biopharma Co., Ltd. ยท Tests: HH2853 Tablets Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL) NCT05833724Phase 26 sites๐Ÿ“ Kaohsiung City๐Ÿ“ Kaohsiung City๐Ÿ“ New Taipei City Great Novel Therapeutics Biotech & Medicals Corporation ยท Tests: Chidamide Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma NCT07388563Phase 11 site๐Ÿ“ Bethesda National Cancer Institute (NCI) ยท Tests: azacitidine, abatacept Pembrolizumab and Olaparib Treatment for Relapsed or Refractory Peripheral T-Cell Lymphoma NCT06160843Phase 21 site๐Ÿ“ Singapore National Cancer Centre, Singapore ยท Tests: Pembrolizumab IV infusion Q3W, with daily oral Olaparib. Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma NCT07502768Phase 1, Phase 21 site๐Ÿ“ Shanghai Rong Tao ยท Tests: Tislelizumab, Zeprumetostat Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies NCT07523555Phase 1, Phase 21 site๐Ÿ“ Shenzhen Beijing Biotech ยท Tests: Autologous CD19/CD22 dual-target CAR-T module, Autologous CD19/CD20 dual-target CAR-T module, Autologous BCMA/CD19 dualโ€ฆ CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas NCT07022964Phase 1, Phase 23 sites๐Ÿ“ Beijing๐Ÿ“ Shanghai๐Ÿ“ Shanghai Beijing GoBroad Hospital ยท Tests: CD5 CAR-T cells infusion Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma NCT06561048Phase 337 sites๐Ÿ“ Duarte๐Ÿ“ Irvine๐Ÿ“ San Francisco Corvus Pharmaceuticals, Inc. ยท Tests: Soquelitinib, Belinostat, Pralatrexate Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells NCT06420076Phase 1, Phase 21 site๐Ÿ“ Beijing Essen Biotech ยท Tests: CD5/CD7 CAR-T Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma NCT07093710Phase 1, Phase 21 site๐Ÿ“ Guangzhou Sun Yat-sen University ยท Tests: Golidocitinib, Mitoxantrone Hydrochloride Liposome, Chidamide A Vaccine (VSV-hIFNฮฒ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma NCT03017820Phase 12 sites๐Ÿ“ Scottsdale๐Ÿ“ Rochester Mayo Clinic ยท Tests: Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma NCT06376721Phase 1, Phase 21 site๐Ÿ“ Beijing Beijing Tongren Hospital ยท Tests: Linperlisib, Camrelizumab, Pegaspargase, Dexamethasone Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma NCT06508463Phase 12 sites๐Ÿ“ Scottsdale๐Ÿ“ Rochester Mayo Clinic ยท Tests: Biopsy, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Positron Emission Tomography A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas NCT07018752Phase 1, Phase 220 sites๐Ÿ“ Caen๐Ÿ“ Clermont-Ferrand๐Ÿ“ Crรฉteil The Lymphoma Academic Research Organisation ยท Tests: roginolisib, golcadomide, azacitidine Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL NCT04747236Phase 26 sites๐Ÿ“ Long Beach๐Ÿ“ New Haven๐Ÿ“ New York University of Virginia ยท Tests: Azacytidine, Romidepsin, Belinostat, Pralatrexate, Gemcitabine RD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer/T Cell Malignancies NCT06732492Phase 11 site๐Ÿ“ Wuhan Union Hospital, Tongji Medical College, Huazhong Universityโ€ฆ ยท Tests: RD13-02 cell infusion Sintilimab and Linperlisib Combination Treatment in Relapsed or Refractory Extranodal Natural Killer/T Cell Lymphoma NCT06793956Phase 11 site๐Ÿ“ Guangzhou Sun Yat-sen University ยท Tests: Sintilimab and Linperlisib Combination Treatment A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype NCT06522737Phase 344 sites๐Ÿ“ Ghent๐Ÿ“ Leuven๐Ÿ“ Prague SecuraBio ยท Tests: Duvelisib, Gemcitabine, Bendamustine A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL NCT06854653Phase 215 sites๐Ÿ“ Duarte๐Ÿ“ Irvine๐Ÿ“ New Haven Prescient Therapeutics, Ltd. ยท Tests: PTX-100 Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma NCT05996185Phase 22 sites๐Ÿ“ New Haven๐Ÿ“ New York Yale University ยท Tests: Mogamulizumab, DA-EPOCH Protocol, CHOEP protocol Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma NCT03011814Phase 1, Phase 24 sites๐Ÿ“ Duarte๐Ÿ“ New York๐Ÿ“ Philadelphia City of Hope Medical Center ยท Tests: Durvalumab, Laboratory Biomarker Analysis, Lenalidomide CD4CAR for CD4+ Leukemia and Lymphoma NCT03829540Phase 16 sites๐Ÿ“ Miami๐Ÿ“ Indianapolis๐Ÿ“ Indianapolis Huda Salman ยท Tests: CD4CAR Phase II Study of Golidocitinib and Benmelstobart in Patients with R/R ENKTL (JACKPOT50) NCT06733051Phase 22 sites๐Ÿ“ Beijing๐Ÿ“ Guangzhou Sun Yat-sen University ยท Tests: Golidocitinib, Benmelstobart A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma NCT06776952Phase 31 site๐Ÿ“ Beijing Evopoint Biosciences Inc. ยท Tests: XNW5004 ; Chidamide placebo, XNW5004 placebo; Chidamide
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy